Renub Research is a leading Market Research and Information Analysis Company with offices at Roswell, USA and Noida, India.

Oct 25, 2017

Europe Multiple Sclerosis Market and Forecast

Europe multiple sclerosis market potential is of more than US$ 5 Billion by 2022. But only more than half this market is expected to be actually achieved. This huge difference between actual market and unmet market is due to gap between number of patients who require multiple sclerosis drugs and number of patients who are receiving disease modifying therapy.

Orals mode of administration is Fast growing disease modifying therapy in the European region

Orals mode of administration is fast growing disease modifying therapy in the European region. Injectables and infusions multiple sclerosis therapies are steadily losing their ground in the European market.

Germany is the clear winner in the Europe multiple sclerosis market

In the Europe multiple sclerosis market, Germany is the clear winner, but its losing its market share year on year. The other important markets in the European region are France, Italy, Spain and United Kingdom.

Unmet Market is the market which can be accomplished; but it has yet not been accomplished due to demand and supply gap. At present DMT receiving patients are less than total number of multiple sclerosis patient numbers.

Top 5 Countries Multiple Sclerosis Market & Patients Treated

1. United Kingdom 2. Germany 3. France 4. Italy 5. Spain

Mode of administration — Market & Patients Treated

1. Injectables2. Infusions3. Orals

Key Questions Answered in the Report?

What is the Europe multiple sclerosis market and its growth potential in near future?

How many number of patients treated by disease modifying therapy in the European region?

What is the multiple sclerosis market in European countries (UK, Germany, France, Italy, and Spain)?

How many multiple sclerosis patients living in European countries?

Which mode of administration (Injectables, Infusions, Orals) is gaining more popularity?